CITA Technology Explained: The extremely high quality of the clinical work combined with the Stanford – CITA technology earned AmeReGen & the CCTC the highest recognition all the way to the director of the US National Cancer Institute NCI, and now the US-FDA even before the decision was made to build a global CITA Cell Pak™ manufacturing and export hub. AmeReGen GC Arabia SP has secured all GC Arabia's exclusive rights to import and distribute exclusively CITA for use as advanced liver cancer drugs. Covered are all products and product developments related to this proprietary, approved, and commercially successfully market-launched class of adult-stem-cell-like CITA cancer products, with therapy brand names of ImmuneRebuild™, ImmunoCure®,& ImmunoShield™. As part of its already 6+-year-proven, cash-flow-positive business model, CITA have treated advanced, multi- drug resistant cancer with great clinical success and without side effects in paying patients in the following advanced and multi-drug resistant (MDR+) cancer indications: small cell and NSC lung cancer, brain cancer, sarcoma, uterine, ovarian, breast, prostate, head and neck, melanoma, liver and blood cancers. This innovative drug class essentially hollows-out cancer from the inside (to the right) and
destroys cancer and its blood-supply from WITHIN and immediately upon
intravenous (IV) contact via an entirely new mechanism. CITA can be
combined with chemo- radiation and surgical cancer treatments but does
NOT need either to work. No pain, complications, or ill side effects (of any grade I-IV) have ever been reported from CITA mono-therapy. modality CITA, Cellular Intravascular Treatment Agents for Cancer is in-licensed from famous Stanford University Stem Cell Transplant R&D Labs & RCH is presently considered the world’s premier routine and ethical adult stem cell treatment for cancer. |
 |
